Cardioprotection – at the heart of long-term haemodialysis
The NEW FX CorDiax dialyser is designed to reduce the risks associated to cardiovascular disease in dialysis patients.
New epidemiological cohort study supports recent ESHOL data
The epidemiological cohort study compared the survival of incident patients on three different treatment modalities: high-flux hemodialysis (HD), low-volume online hemodiafiltration (OL-HDF) and HighVolume OL-HDF.1
Fresenius Medical Care shared recent study results on HighVolume HDF, as well as APD
This year’s ANZSN provided Fresenius Medical Care the opportunity to share the latest insights into new therapy modalities in Haemodialysis, as well as Peritoneal Dialysis.
A new study provides insights into the cost of peritoneal dialysis versus haemodialysis across the world including Australia
While peritoneal dialysis (PD) has a number of advantages, including the possibility of it being offered in remote locations, it remains an underused modality in most parts of the world. Here we report results from a global analysis demonstrating that PD offers improved or at least similar cost-effectiveness to haemodialysis (HD) in the majority of countries.1
The new 5008 Therapy System - Beyond your expectations
The new ‘5008 Therapy System – Beyond your expectations’ provides enhanced therapy options, safety features and handling capabilities further improving management of ESRD.